Retatrutide vs Semaglutide: A Head-to-Head Data Comparison

Retatrutide and semaglutide sit at opposite ends of the same drug class. Semaglutide has been on the market since 2017, with the weight loss indication (Wegovy) approved in 2021 based on STEP 1 data showing an average 14.9% body weight reduction at the 2.4mg weekly dose over 68 weeks (Wilding et al., NEJM 2021). Retatrutide is not yet approved anywhere in the world. Its first Phase III readout, TRIUMPH-4 (NCT05931367), reported in December 2025 and put the 12mg dose at 28.7% body weight reduction across the same 68-week window.

That headline gap (roughly double the weight loss) is the main reason this comparison exists. But the picture underneath matters. Semaglutide has years of real-world safety data, a cardiovascular outcomes trial (SELECT) showing reduced major adverse events, and actual availability through pharmacies. Retatrutide has a stronger efficacy profile in the trials run so far, a new safety signal (dysesthesia) that wasn't present in Phase II, and a regulatory pathway that keeps it out of patient hands until at least 2027.

This article walks through the mechanisms, the trial evidence, the practical differences in dosing and side effects, and the comparative context most readers actually need. All figures below come from published trial data or Eli Lilly's December 2025 press release, cited where possible.

What the two compounds are

Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone glucagon-like peptide-1, which is released by L-cells in the intestine after meals. Activating the GLP-1 receptor slows gastric emptying, increases insulin secretion in response to glucose, reduces glucagon release, and acts centrally on appetite pathways. Semaglutide is marketed as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus for oral diabetes treatment.

Retatrutide (Eli Lilly's LY3437943) is a first-in-class triple hormone receptor agonist. It activates GLP-1 receptors (same mechanism as semaglutide), GIP receptors (glucose-dependent insulinotropic polypeptide, the second receptor that tirzepatide also hits), and glucagon receptors. The glucagon component is the novel piece: glucagon receptor activation in the liver and adipose tissue is thought to increase basal energy expenditure and promote fat oxidation. Semaglutide's mechanism reduces calorie intake. Retatrutide's mechanism reduces intake and raises expenditure.

The pharmacological distinction matters because it explains both the larger weight loss and the different safety profile. On semaglutide, the ceiling on efficacy is roughly the ceiling on tolerable appetite suppression: once a patient's food intake drops enough, the drug cannot pull weight down further. The glucagon agonism in retatrutide opens a second lever. Even if appetite suppression plateaus, basal metabolic rate and hepatic fat oxidation continue pulling on body weight. That is the mechanistic argument for why retatrutide's weight loss curves in both Phase II and TRIUMPH-4 did not flatten out by week 48, and why TRANSCEND-T2D-1 showed continued reduction at week 40.

Both compounds are lipidated peptides designed for a long half-life and weekly dosing. Semaglutide's half-life is around 165 hours (about seven days). Retatrutide's is similar at approximately six days. Both are subcutaneous injections using prefilled pens or auto-injectors in their trial and commercial forms. Neither has an oral weight-loss indication, though oral semaglutide exists for diabetes (Rybelsus) and Lilly's oral orforglipron is advancing separately.

What the research says

The most directly comparable data points are the Phase III primary obesity trials for each compound.

Semaglutide: STEP 1 and the broader STEP programme

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021; NCT03548935) randomised 1,961 adults with overweight or obesity (no type 2 diabetes) to semaglutide 2.4mg weekly or placebo for 68 weeks, alongside lifestyle intervention. Mean body weight change was -14.9% with semaglutide versus -2.4% with placebo. STEP 2 tested semaglutide in adults with type 2 diabetes and showed -9.6% at 2.4mg. STEP 3 layered on intensive behavioural therapy and produced -16.0%. STEP 4 showed what happens when treatment is withdrawn: patients who switched to placebo regained a substantial fraction of lost weight, while those continuing semaglutide kept losing. STEP 5 extended treatment to two years and reported sustained reductions of around -15.2%.

Beyond weight, the SELECT trial (Lincoff et al., NEJM, 2023) tested semaglutide 2.4mg in 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. Over a median 40 months, semaglutide produced a 20% relative risk reduction in the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. SELECT is the strongest outcomes data in the GLP-1 class for weight management and is a meaningful advantage semaglutide currently holds over every other compound in the comparison.

Retatrutide: TRIUMPH-4, Phase II, and what's still pending

The Phase II obesity trial (Jastreboff et al., NEJM, 2023) tested retatrutide across multiple doses in 338 adults over 48 weeks. The 12mg arm produced a mean body weight reduction of -24.2%, with no plateau visible at the end of the study. That figure set the expectation for Phase III. The same Phase II programme also reported a striking liver outcome: in the subgroup with elevated liver fat, retatrutide reduced intrahepatic fat (measured by MRI-PDFF) by up to 86% at the highest dose, an effect size larger than anything previously published in the class.

TRIUMPH-4 (NCT05931367) reported topline results on December 11, 2025. The trial enrolled 1,632 adults with obesity and knee osteoarthritis. At 68 weeks, the 12mg dose produced -28.7% body weight reduction, the 9mg dose produced -26.4%, and placebo produced -2.1%. Systolic blood pressure fell by 14.0 mmHg at 12mg. WOMAC pain scores improved by -4.4 points at 12mg versus -2.4 on placebo. Cardiovascular risk markers improved across the board.

Seven more Phase III readouts from the TRIUMPH programme are expected through 2026, including TRIUMPH-1 (general obesity, the pivotal NDA trial), TRIUMPH-2 (obesity with type 2 diabetes), and TRIUMPH-3 (cardiovascular outcomes). The cardiovascular outcomes readout is the one that will determine whether retatrutide can compete directly with semaglutide's SELECT data. Until TRIUMPH-3 reports, semaglutide has the documented outcomes advantage.

The diabetes picture

TRANSCEND-T2D-1, reported by Eli Lilly on March 19, 2026, was the first Phase III retatrutide trial in type 2 diabetes. At 12mg over 40 weeks, participants saw a 2.0% A1C reduction and 16.8% body weight loss. For context, semaglutide 1.0mg in the SUSTAIN trials produced roughly 5% to 7% weight loss in diabetes populations. Weight loss in TRANSCEND-T2D-1 had not plateaued at week 40, which is unusual for the class.

Practical breakdown: dosing, administration, tolerability

Both are once-weekly subcutaneous injections. Both require titration to manage gastrointestinal side effects. The schedules differ.

Semaglutide titration (Wegovy)

• Weeks 1 to 4: 0.25mg weekly
• Weeks 5 to 8: 0.5mg weekly
• Weeks 9 to 12: 1.0mg weekly
• Weeks 13 to 16: 1.7mg weekly
• Week 17 onward: 2.4mg weekly (maintenance)

Retatrutide titration (as used in TRIUMPH-4)

• Weeks 1 to 4: 2mg weekly
• Weeks 5 to 8: 4mg weekly
• Weeks 9 to 12: 6mg weekly
• Weeks 13+: 8mg, 9mg, or 12mg maintenance depending on arm

The trial titration is slower than what has been reported in research-use-only protocols circulating online. Lilly's approach was designed to minimise gastrointestinal intolerance and discontinuation. Even with that schedule, discontinuation rates in TRIUMPH-4 were 12.2% at 9mg and 18.2% at 12mg, compared to 4% on placebo. Some of the discontinuations were attributed to "perceived excessive weight loss" in participants with lower baseline BMI.

Common adverse events were broadly similar across the two compounds at class-typical rates: nausea, diarrhea, vomiting, constipation. Retatrutide at 12mg reported nausea in 43%, vomiting in 21%, and diarrhea in 33% of participants. The notable divergence is dysesthesia, reported in 8.8% of patients at 9mg retatrutide and 20.9% at 12mg, against 0.7% on placebo. Dysesthesia is an abnormal skin sensation (tingling, burning, numbness) that was not reported in Phase II. Lilly stated these events did not generally lead to discontinuation, but analysts flagged the signal as something to track across the remaining TRIUMPH readouts.

Two other practical points worth flagging. First, TRIUMPH-4 reported that some of the discontinuations at 12mg were driven by what Lilly described as "perceived excessive weight loss" in participants with lower baseline BMI. The rate of weight loss was, for some participants, uncomfortably fast. In a real-world setting, that suggests the 9mg dose may become the effective maintenance dose for many patients, with 12mg reserved for those with higher starting weight or plateaued progress. Second, semaglutide's tolerability improves significantly with slower titration. Clinicians sometimes extend the STEP titration schedule from 16 weeks to 20 or 24 weeks to reduce nausea, a lever that may also apply to retatrutide once the label arrives.

Direct comparison table

How to think about the gap

Cross-trial comparisons are imperfect. STEP 1 enrolled a different population (adults with overweight or obesity without diabetes) to TRIUMPH-4 (adults with obesity and knee osteoarthritis). Both trials were 68 weeks, both compared against placebo with lifestyle support, but no head-to-head trial has been run. A direct comparison would be the only way to remove trial design as a confound. For now, the fair statement is: under broadly similar conditions, retatrutide 12mg produces weight loss roughly double that of semaglutide 2.4mg.

The other half of the comparison is risk and access. Semaglutide has been prescribed to millions of patients, has a published cardiovascular outcomes trial (SELECT) showing 20% relative risk reduction in major adverse cardiovascular events, and has known pricing through insurance channels. Retatrutide has stronger efficacy in the trials run so far but a smaller evidence base overall, a safety signal (dysesthesia) that needs characterising, and no pathway to prescription availability before 2027 at the earliest.

Access is the point that most comparisons gloss over. Even for semaglutide, the picture is messy: Novo Nordisk shortages through 2023 and 2024 pushed many patients to compounded semaglutide from 503A and 503B pharmacies. The FDA removed semaglutide from the drug shortage list in early 2025, which ended the legal basis for most compounding. Patients on compounded versions had to switch back to branded Wegovy or Ozempic, pay out of pocket, or move to other compounds. Retatrutide's eventual approval will likely reset the supply dynamic again, and Lilly's manufacturing capacity is one of the unknowns that may constrain the early rollout.

On price, Wegovy's US list price sits around $1,350 per month, with substantial variation by insurance coverage and manufacturer copay programmes. Analyst estimates put retatrutide at $1,200 to $1,500 per month at launch. Medicare does not currently cover weight-loss medications, and commercial coverage is patchy. Patients paying out of pocket will see similar monthly outlays for either compound, with retatrutide's advantage being potentially faster time-to-target-weight (meaning fewer total months of treatment to reach goal).

For readers looking at this from a clinical or practical angle, the calculation usually reduces to: how much does the extra weight loss matter, how much does waiting two or three years cost, and how much of the long-term safety picture can you accept being unknown. Our Retatrutide File covers the compound in depth, our Semaglutide File covers the approved GLP-1, and the three-way comparison includes tirzepatide (currently the strongest approved option at around 22.5% weight loss in SURMOUNT-1).

Frequently asked questions